Neuvasq

3 known investors

Neuvasq Biotechnologies is a biotech spin-off from the Université libre de Bruxelles developing therapies that target the Gpr124/Reck signaling complex to repair the blood-brain and blood-CNS barriers in neurological and cerebrovascular disorders. The company translates research on brain vasculature and the blood-brain barrier into drug development programs.